Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 62, Issue 3, Pages 346-361Publisher
ELSEVIER
DOI: 10.1016/j.addr.2009.11.007
Keywords
Gold nanoparticles; Drug delivery; EGFR; Tyrosine kinase; Anti-cancer drugs; Pancreatic cancer; Colloidal gold nanoparticles; AuNPs; Fabrication; Targeted therapy
Categories
Funding
- [CA136494]
- [CA135011]
Ask authors/readers for more resources
The targeted delivery of a drug should result in enhanced therapeutic efficacy with low to minimal side effects. This is a widely accepted concept, but limited in application due to lack of available technologies and process of validation. Biomedical nanotechnology can play an important role in this respect. Biomedical nanotechnology is a burgeoning field with myriads of opportunities and possibilities for advancing medical science and disease treatment. Cancer nanotechnology (1-100 nm size range) is expected to change the very foundations of cancer treatment, diagnosis and detection. Nanomaterials, especially gold nanoparticles (AuNPs) have unique physico-chemical properties, such as ultra small size, large surface area to mass ratio, and high surface reactivity, presence of surface plasmon resonance (SPR) bands, biocompatibility and ease of surface functionalization. In this review, we will discuss how the unique physico-chemical properties of gold nanoparticles may be utilized for targeted drug delivery in pancreatic cancer leading to increased efficacy of traditional chemotherapeutics. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available